Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

"Competing interests: The authors declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: K.N. reports support for attending meetings and/or travel by Chiesi Pharmaceuticals GmbH and TEVA-Ratiopharm Arzneimittel Vertriebs-GmbH, outside the submitted work. V.G. and C.R.-N. have nothing to disclose. D.A. reports support for attending meetings and/or travel by Mylan Austria GmbH, Vertex Pharmaceuticals and TEVA-Ratiopharm Arzneimittel Vertriebs-GmbH, outside the submitted work. J.E. reports support for attending meetings and/or travel by Corbus Pharmaceuticals GmbH and Chiesi Pharmaceuticals GmbH. T.F. reports support for attending meetings and/or travel by Mylan Austria GmbH and Vertex Pharmaceuticals, outside the submitted work. L.N. reports grants or contracts from German Center for Lung Research, Vertex Pharmaceuticals and Boehringer Ingelheim (for study participation), outside the submitted work. Furthermore, he is a member of the trial steering committee for CF STORM, the medical leader of the German CF registry as well as the manager of the pharmacovigilance study of the ECFS and editorial supporter of Articulate Science LLC. H.E. reports grants or contracts with Vertex Pharmaceuticals (for study participation), outside the submitted work. Furthermore, he received personal support for presentations and for advisory board by Vertex Pharmaceuticals as well as by TEVA-Ratiopharm Arzneimittel Vertriebs-GmbH and Chiesi Pharmaceuticals support for attending meetings."

"Funding: The authors received no financial support for the research, authorship and/or publication of this article."